This was worth $25 recently after the PMS trial and would still be close to this price were it not for the short report. Almost all brokers still value this between $25 and $35 right now without any further trial success.
Add in 2 P3 successes, some more positive earnings reports for Daybue and now possibly a Canadian approval in CY24 and Jon's hint in the Annual Report for more indications for 2591. What is it worth?
I will say it again for the short sighted among us - we are worth more than Reata on Daybue alone, which gives us a SP of circa $85. If 2591 is worth 5 times as mush, assuming similar drug pricing, then how is this only worth $50 in any TO scenario.
When I ran my model, I got to $15b USD and I was very conservative. When KJT ran their model recently, they came in significantly higher.
Not sure where the disconnect is but there is no way that we are worth less than Reata. I really wish someone would explain to me how we are worth considerably less in a cogent manner.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)